US Patent 7,754,702: Scope, Claims, Expiration, and Ferric Carboxymaltose Patent Landscape
US Patent 7,754,702 protects high-dose, rapid administration of non-immunogenic iron-carbohydrate complexes, with the most commercially relevant claims directed to intravenous ferric carboxymaltose. The broadest independent claim covers at least 600 mg of elemental iron in a single dosage unit. Claim 55 is narrower but more commercially targeted: at least 1,000 mg of ferric carboxymaltose, administered intravenously in 200-300 mL of diluent within five minutes or less, with specified particle and iron-core dimensions.
The patent is method-of-treatment intellectual property rather than a basic composition patent. Its practical relevance is greatest for Injectafer/Ferinject-type ferric carboxymaltose products and competing products that reproduce the claimed dose, administration speed, formulation concentration, and physicochemical properties.
What does US Patent 7,754,702 protect?
US 7,754,702 protects methods of treating iron deficiency or dysfunctional iron metabolism by administering a high single dose of an iron-carbohydrate complex. The patent claims cover:
- A minimum dose of approximately 600 mg elemental iron.
- Higher thresholds of 700 mg, 800 mg, 900 mg, 1,000 mg, 1,500 mg, 2,000 mg, and 2,500 mg.
- Administration within 15, 10, five, or two minutes.
- Intravenous infusion, intravenous bolus injection, or intramuscular injection.
- Ferric carboxymaltose, iron mannitol, iron polymaltose, iron gluconate, iron sorbitol, and iron polyglucose sorbitol carboxymethyl ether.
- Treatment of iron deficiency anemia, anemia of chronic disease, impaired iron absorption, poor nutrition, blood donation, hair loss, and attention deficit disorder.
- Repeat administration one day to 12 months after the first dose.
- Formulations with specified iron-core size, particle size, elemental iron content, carbohydrate content, molecular weight, pH, osmolarity, and blood half-life.
The independent claims are claims 1 and 55. Claim 1 is broad across several iron-carbohydrate complexes and medical conditions. Claim 55 is narrower and focuses on rapid intravenous administration of at least 1,000 mg of ferric carboxymaltose.
How are the independent claims structured?
Claim 1: broad high-dose treatment claim
Claim 1 requires all of the following:
| Limitation |
Requirement |
| Therapeutic purpose |
Treatment of a disease, disorder, or condition involving iron deficiency or dysfunctional iron metabolism |
| Biological result |
Reduced bioavailability of dietary iron |
| Patient |
Subject in need of treatment |
| Product |
An iron-carbohydrate complex |
| Dose |
At least about 0.6 grams of elemental iron in a single dosage unit |
| Complex options |
Iron carboxymaltose, mannitol, polymaltose, gluconate, or sorbitol complex |
| Carbohydrate |
Substantially non-immunogenic |
| Immunology |
Substantially no cross-reactivity with anti-dextran antibodies |
| Exclusion |
Restless Leg Syndrome is excluded |
The claim does not require intravenous administration. A product administered intramuscularly, or potentially by another parenteral route, could fall within claim 1 if the remaining limitations are met.
The claim also does not require a particular treatment duration, dilution volume, infusion rate, or particle-size profile. Those limitations appear in dependent claims and claim 55.
Claim 55: commercially focused rapid-infusion claim
Claim 55 requires:
- Treatment of iron deficiency or dysfunctional iron metabolism.
- Ferric carboxymaltose.
- At least 1,000 mg of elemental iron in a single dosage unit.
- Intravenous administration.
- Approximately 200-300 mL of diluent.
- Administration in approximately five minutes or less.
- Mean iron-core size of 1-9 nm.
- Mean particle size no greater than 35 nm.
- Intravenous infusion or intravenous injection.
Claim 55 is more difficult to design around than claim 1 for a product that uses a standard 1,000 mg ferric carboxymaltose dose delivered rapidly. It is also more vulnerable to disputes over measurement methods, product specifications, and the meaning of "about."
What products and active ingredients are most directly implicated?
The commercial product most closely associated with the patent is ferric carboxymaltose, marketed as Injectafer in the United States and Ferinject in many other markets. Injectafer is ferric carboxymaltose injection, marketed in the United States by American Regent, Inc. under NDA 203565.[2]
Ferric carboxymaltose is a polynuclear iron(III)-hydroxide complex stabilized by a carbohydrate ligand. The claims identify the complex using structural and manufacturing language associated with ferric carboxymaltose, including:
- Approximately 24%-32% elemental iron.
- Approximately 25%-50% carbohydrate.
- Molecular weight ranges of approximately 100,000-350,000 daltons.
- A mean iron-core size of approximately 1-9 nm.
- A mean particle size of no more than approximately 35 nm.
- A nominal composition of approximately 28% elemental iron and 150,000 daltons in claim 26.
The claim language is directed to the complex as administered in a treatment method. It does not broadly claim every ferric carboxymaltose composition independent of use.
What diseases and patient populations are covered?
Iron deficiency anemia
Claims 2-4 cover anemia and iron deficiency anemia. Claim 4 lists a wide range of associated conditions, including:
- Chronic or acute blood loss.
- Pregnancy and childbirth.
- Heavy uterine bleeding and menstruation.
- Gastrointestinal bleeding.
- Chronic kidney disease and dialysis.
- Surgery and acute trauma.
- Parasitic infection.
- Chronic recurrent hemoptysis.
- Chronic ingestion of alcohol, salicylates, steroids, nonsteroidal anti-inflammatory drugs, or erythropoiesis-stimulating agents.
Anemia of chronic disease
Claims 5 and 6 extend coverage to anemia associated with rheumatoid arthritis, cancer, leukemia, chemotherapy, inflammatory bowel disease, ulcerative colitis, hepatitis, systemic lupus erythematosus, congestive heart failure, cardiomyopathy, and other listed disorders.
Malabsorption and poor nutrition
Claims 7 and 8 address anemia caused by impaired iron absorption or poor nutrition, including Crohn's disease, gastric surgery, iron-absorption-inhibiting drugs, and chronic calcium use.
Other indications
Claim 9 covers blood donation, hair loss, and attention deficit disorder. These indications create a broader theoretical scope but have less obvious relevance to the current FDA-labeled commercial use of Injectafer.
The Restless Leg Syndrome exclusion in claim 1 is material. A treatment directed solely to Restless Leg Syndrome would not satisfy claim 1, although other claims or separate patent families could still be relevant depending on their language.
What formulations and manufacturing characteristics are protected?
Ferric carboxymaltose formulation parameters
Claims 21-27 and 30-40 define the complex through physicochemical parameters:
| Parameter |
Claimed range |
| pH |
Approximately 5.0-7.0 |
| Iron-core size |
No greater than approximately 9 nm |
| Narrow iron-core subrange |
Approximately 3-7 nm, including 4-5 nm |
| Mean particle size |
No greater than approximately 35 nm |
| Narrow particle-size subrange |
Approximately 6-7 nm |
| Elemental iron |
Approximately 24%-32% |
| Carbohydrate |
Approximately 25%-50% |
| Molecular weight |
Approximately 90,000-800,000 daltons |
| Ferric carboxymaltose molecular weight |
Approximately 100,000-350,000 daltons |
| Blood half-life |
Approximately 10-20 hours |
| Osmolarity |
Physiological |
A claim is infringed only if the accused product and administration meet every limitation of the asserted claim. The presence of ferric carboxymaltose alone is not enough for claims requiring dose, infusion time, dilution volume, or particle-size limitations.
Manufacturing process limitation
Claims 25 and 56 require ferric carboxymaltose obtained from:
- An aqueous iron(III) salt solution.
- An aqueous solution of an oxidized maltodextrin product.
- Oxidation using aqueous hypochlorite under alkaline conditions.
- Maltodextrin dextrose equivalent generally between approximately 5 and 20.
This limitation may create a manufacturing-IP barrier. A generic applicant may attempt to avoid infringement by using a different carbohydrate oxidation route, different starting materials, or a process that produces an equivalent product without satisfying the claimed process provenance. The resulting product could still implicate product-by-property or treatment claims if it has the claimed physicochemical characteristics and is used in the claimed manner.
How strong is the patent estate for high-dose ferric carboxymaltose?
The patent has meaningful commercial scope but a narrower enforcement profile than a composition-of-matter patent.
Strengths
- Claim 55 maps closely to a standard 1,000 mg ferric carboxymaltose administration.
- The claim combines dose, route, infusion time, dilution volume, and particle characteristics.
- A generic product may be commercially designed to match the reference product's administration instructions.
- Treatment claims can create exposure even when a generic applicant avoids copying a manufacturing process.
- Claims 23-27 and 56-57 specifically target ferric carboxymaltose and its chemical identity.
Weaknesses
- The patent does not claim ferric carboxymaltose as a composition in isolation.
- "About," "substantially non-immunogenic," and "substantially no cross reactivity" invite claim-construction disputes.
- Particle size and iron-core size depend on analytical method, sample preparation, and measurement conditions.
- A generic applicant may seek a label that omits or narrows the patented administration regimen.
- Prior art involving intravenous iron-carbohydrate complexes, high-dose iron replacement, and rapid infusion could support obviousness or anticipation challenges.
- The broad disease language may be vulnerable where the accused treatment is not directed to a condition that reduces dietary iron bioavailability.
The strongest assertion position is likely claim 55 against a product using a 1,000 mg intravenous ferric carboxymaltose dose in approximately 200-300 mL over five minutes or less. The strongest design-around position is a materially different dose, infusion duration, dilution protocol, or product profile, provided the alternative does not satisfy another asserted claim.
When does US Patent 7,754,702 lose exclusivity?
The patent issued on July 13, 2010.[1] Its relevant nonprovisional filing date was August 23, 2004, and the ordinary 20-year patent-term baseline would therefore be August 23, 2024, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and any applicable regulatory restoration.[1,3]
| Event |
Date or status |
| Earliest priority date reported for the family |
August 22, 2003 |
| US filing date |
August 23, 2004 |
| Patent publication |
March 2, 2006 |
| Patent grant |
July 13, 2010 |
| Ordinary 20-year baseline from US filing |
August 23, 2024 |
| Possible adjustment |
Must be determined from the USPTO patent-term calculation |
| Possible FDA regulatory extension |
Must be determined from the applicable FDA and USPTO records |
Patent expiration should not be stated solely from the grant date. For a patent filed after June 8, 1995, the relevant term generally runs 20 years from the earliest effective nonprovisional filing date, not 20 years from issuance.[3] PTA and PTE can alter the final enforceable date.
The patent's practical exclusivity must also be separated from FDA regulatory exclusivity. FDA approval of Injectafer occurred on July 25, 2013, and regulatory exclusivity periods do not necessarily expire on the same date as patent protection.[2,4]
What is the Orange Book status of US 7,754,702?
Injectafer is an FDA-approved drug product listed in the Orange Book under NDA 203565.[2,4] The Orange Book identifies patents submitted by an NDA holder or applicant as covering the approved drug, its use, or both. An Orange Book listing does not establish that every claim is valid or infringed.
For ferric carboxymaltose, the key regulatory question is whether US 7,754,702 remains listed for the relevant Injectafer presentation and whether the listed claims cover the drug, an approved method of use, or both. Patent-listing status can change through corrections, delistings, expiration, or litigation-related events. The listing must therefore be read together with the current FDA Orange Book entry and the patent's USPTO term data.[4]
What Paragraph IV challenges and generic-entry risks exist?
A generic ferric carboxymaltose applicant would generally submit an ANDA and certify under Paragraph IV that one or more listed patents are invalid, unenforceable, or not infringed.[5] A Paragraph IV notice can trigger patent litigation under 35 U.S.C. §271(e)(2), which may result in a 30-month stay of final FDA approval, subject to statutory exceptions and court developments.[5]
Likely generic arguments
A challenger could attack the patent on several grounds:
- Anticipation by prior disclosures of high-dose intravenous iron complexes.
- Obviousness based on combining known ferric carboxymaltose formulations with known high-dose infusion regimens.
- Indefiniteness of "about," "substantially non-immunogenic," and particle-size limitations.
- Lack of written description or enablement for the full range of complexes and diseases.
- Non-infringement based on infusion time, dilution volume, dose, or analytical particle-size results.
- Process non-infringement for claims 25 and 56.
- Label-based defenses where the generic label omits a patented indication or administration method.
Generic launch scenarios
| Scenario |
Commercial effect |
| Patent invalidated before final approval |
Earlier unrestricted ANDA launch may occur |
| Patent held valid and infringed |
Launch may be delayed until expiration or settlement date |
| Label carve-out accepted |
Generic may launch for non-patented uses or regimens |
| Settlement with licensed entry |
Entry occurs on a negotiated date, potentially before patent expiry |
| Non-infringing formulation or administration protocol |
Launch may proceed with litigation risk reduced |
| At-risk launch |
Generic enters before final resolution and faces damages or injunction risk |
The risk is concentrated in products that copy Injectafer's 1,000 mg rapid-infusion regimen. A generic that uses a longer infusion period or a different concentration may reduce exposure to claim 55 but must be assessed against claims 1, 10-20, 41-50, and any later patents.
Which companies compete with ferric carboxymaltose?
Ferric carboxymaltose competes in the intravenous iron market with products using different complexes and different patent estates.
| Product |
Active iron complex |
Manufacturer or marketer |
Principal differentiation |
| Injectafer |
Ferric carboxymaltose |
American Regent |
High-dose IV iron; rapid administration |
| Venofer |
Iron sucrose |
Vifor or authorized commercial partners |
Established use, generally fractionated dosing |
| Feraheme |
Ferumoxytol |
AMAG Pharmaceuticals, now associated with Covis |
Large-dose IV iron with separate formulation profile |
| Monoferric |
Ferric derisomaltose |
Pharmacosmos |
High-dose iron replacement |
| Ferrlecit |
Sodium ferric gluconate |
Sanofi and other suppliers |
Lower-dose iron replacement, especially dialysis |
| INFeD |
Iron dextran |
Various manufacturers |
Older dextran-based formulation |
The patent's anti-dextran limitation is important in this competitive context. Iron dextran products may not satisfy the requirement of a carbohydrate component with substantially no cross-reactivity with anti-dextran antibodies. Conversely, a non-dextran complex may still be accused if it meets the other claim limitations.
Are biosimilars a risk to US 7,754,702?
Biosimilar risk is low because ferric carboxymaltose is not a biologic regulated through the biosimilar pathway. A competing ferric carboxymaltose product would generally pursue an ANDA or another applicable drug pathway, not a 351(k) biosimilar application.[6]
The principal competitive threat is therefore generic or follow-on intravenous iron entry. The technical challenge is pharmaceutical equivalence and comparability of a complex iron-carbohydrate product. FDA review may focus on the active ingredient, impurities, particle characteristics, carbohydrate structure, stability, and manufacturing controls. These factors can create regulatory and manufacturing barriers even after patent expiry.
What patent landscape surrounds Injectafer and ferric carboxymaltose?
US 7,754,702 is one element of a broader patent landscape that can include:
- Ferric carboxymaltose composition patents.
- Manufacturing-process patents.
- Particle-size and molecular-weight specifications.
- Injectable formulations and concentration ranges.
- Rapid infusion and bolus administration methods.
- Specific treatment indications.
- Pediatric, chronic kidney disease, heart failure, and other later-approved uses.
- Device, vial, packaging, and stability claims.
The principal freedom-to-operate question is not whether a product contains ferric carboxymaltose. It is whether the product's approved label, actual administration instructions, manufacturing process, and measurable product attributes jointly satisfy one or more unexpired claims.
A company planning an ANDA should separately map:
- The current Orange Book patent list.
- All unexpired US family members and continuations.
- Terminal disclaimers.
- PTA and PTE records.
- Paragraph IV certifications.
- District-court litigation and Federal Circuit decisions.
- Settlement licenses and launch dates.
- Non-Orange-Book method-of-use and process patents.
What litigation and settlement issues matter?
A complete litigation conclusion cannot be drawn from the claims text alone. The patent's litigation significance depends on whether the NDA holder listed it, whether an ANDA applicant served a Paragraph IV notice, which claims were asserted, and whether any court has construed or invalidated them.
The most material litigation issues would be:
- Whether claim 55 covers the reference product's FDA-approved infusion regimen.
- Whether "about five minutes or less" includes the labeled administration time.
- Whether 200-300 mL of diluent is met by the product label or actual clinical practice.
- Whether iron-core and particle-size measurements are reliable and reproducible.
- Whether a generic label can omit the patented use.
- Whether a settlement grants an authorized-generic or licensed-entry right.
- Whether process claims can be enforced without access to the generic manufacturer's confidential process.
An ANDA litigation strategy would likely assert non-infringement and invalidity in parallel. The patent holder would focus on the practical equivalence between the proposed generic regimen and the Injectafer regimen.
What is the commercial exposure from this patent?
Injectafer is a major product in the US intravenous iron market. Patent exposure is commercially significant because the patented regimen supports administration of a large replacement dose in one visit rather than multiple lower-dose administrations.
Revenue exposure depends on:
- US Injectafer sales.
- Share held against Monoferric, Feraheme, Venofer, and Ferrlecit.
- The number of ANDA applicants.
- The earliest settlement or court-authorized launch date.
- Whether generic entrants copy the 1,000 mg rapid-infusion protocol.
- Payer substitution and hospital formulary behavior.
- The ability of the originator to rely on later patents after US 7,754,702 expires.
A first generic entrant could face less exposure if it launches with a carved-out label or a slower administration protocol. Multiple entrants would increase price erosion, contracting pressure, and substitution risk.
Key Takeaways
- US 7,754,702 is a method-of-treatment patent centered on high-dose administration of iron-carbohydrate complexes.
- Ferric carboxymaltose is the most commercially relevant covered complex.
- Claim 1 broadly requires at least approximately 600 mg of elemental iron in a single dosage unit.
- Claim 55 is the principal commercial claim for a 1,000 mg intravenous ferric carboxymaltose dose administered in 200-300 mL within five minutes or less.
- The patent also claims particle size, iron-core size, molecular weight, elemental iron content, carbohydrate content, and manufacturing characteristics.
- It is not a pure composition-of-matter patent, which creates more opportunities for label, dosing, formulation, and process design-arounds.
- The ordinary patent-term baseline is August 23, 2024, subject to PTA, PTE, terminal-disclaimer, and related term records.
- Ferric carboxymaltose competition is a generic-drug issue, not a biosimilar issue.
- The highest infringement risk applies to products replicating Injectafer's dose, infusion time, dilution volume, and product specifications.
- Orange Book status, later family members, litigation, and settlement terms must be evaluated as a portfolio rather than through US 7,754,702 alone.
FAQs
Does US 7,754,702 cover all ferric carboxymaltose products?
No. The patent claims specified treatment methods. A ferric carboxymaltose product must also be used in a claimed dose, route, timing, patient population, or formulation context.
Can a generic avoid claim 55 by administering 1,000 mg over more than five minutes?
Potentially. A longer infusion could avoid the express five-minute limitation in claim 55, but claims 1, 10-20, 41-50, and other unexpired patents would still require review.
Does the patent cover iron dextran?
The claims require a substantially non-immunogenic carbohydrate component with substantially no cross-reactivity with anti-dextran antibodies. Conventional iron dextran products may not meet that limitation.
Is ferric carboxymaltose a biologic for FDA purposes?
No. Ferric carboxymaltose is regulated as a drug product, and competing products generally pursue an ANDA or another drug-approval route rather than a biosimilar application.
Can a generic launch after the patent's ordinary 20-year term?
Not necessarily. A generic may face PTA, PTE, later continuation patents, other Orange Book-listed patents, non-listed process patents, or litigation settlements that affect the effective launch date.
References
- United States Patent and Trademark Office. (2010). U.S. Patent No. 7,754,702, methods of treating iron deficiency with iron carbohydrate complexes.
- U.S. Food and Drug Administration. (2013). Injectafer prescribing information. American Regent, Inc.
- United States Code, 35 U.S.C. §154. Patent term.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
- United States Code, 21 U.S.C. §355(j); 35 U.S.C. §271(e)(2). Abbreviated new drug applications and patent litigation.
- U.S. Food and Drug Administration. (n.d.). Biosimilar and interchangeable products.
